T2D AstraZeneca Farxiga

AstraZeneca reports positive data from type 2 diabetes Phase III trial

AstraZeneca has reported positive results from the Phase III DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) of Farxiga (dapagliflozin) against…